CJC-1295 research guide for Guardo. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
Most researchers seeking out CJC-1295 in Guardo immediately realize that local retail options are nearly impossible to find. This matters because CJC-1295 quality varies dramatically across the market — from analytically confirmed high-purity product to mislabeled or underdosed compounds — and the vendor is the entire quality system. What consistently distinguishes top CJC-1295 vendors is complete batch-specific analytical documentation: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for safety screening. Use this guide to evaluate CJC-1295 vendors rigorously — the framework here apply whether you are in Guardo or anywhere else.
CJC-1295: What the Research Shows
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Guardo studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Source CJC-1295 — Vendor Guide
Quality CJC-1295 sourcing begins with a simple filter: does this vendor make batch-matched COAs available before purchase? Those who make this data freely available are operating transparently. Endotoxin testing in the COA is critical for any injectable research use — endotoxins from microbial contamination can trigger severe inflammatory responses even at very low concentrations. For Guardo researchers evaluating vendors with limited track records: a small initial order to verify quality before scaling up your order is standard practice in the community. The powdered lyophilised form of CJC-1295 is always preferable to liquid pre-made solutions — lyophilised powder retains potency for years in frozen storage, while liquid preparations break down rapidly even under refrigeration.
Order CJC-1295 — ships to Guardo
COA-verified · International tracking · Research grade
All use of CJC-1295 in Guardo or anywhere must be research use only — this compound is not approved for clinical human use, and all handling should adhere to research compound handling standards. Lyophilised CJC-1295 should be frozen at −20°C as soon as it arrives; repeated freeze-thaw cycles of reconstituted material should be avoided by dividing into single-dose aliquots before freezing. Verify the endotoxin level in your CJC-1295 batch COA before any injectable research application — look for results expressed as EU/mg or EU/mL and compare against acceptable research limits for your application. PubMed and related preprint servers are the primary literature resources for CJC-1295 research; favour indexed journal publications over preprints over conference abstracts or single case observations.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
